Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaiyang Ding

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
American Journal of Hematology|April 26, 2026
Outcomes With First-Line PD1 Inhibitors in Extranodal NK/T-Cell Lymphoma: A Comparative Analysis From a 755-Patient Multicenter CohortHailing Liu, Mei Sun, Chunling Wang, et al.
Haematologica|July 9, 2026
Dual resistance to asparaginase and PD-1 blockade in extranodal natural killer/T-cell lymphoma: dismal outcomes from a multicenter cohortRan Li, Lixia Sheng, Jie Ma, et al.
Chinese Medical Journal|May 29, 2025
Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myelomaWenting Chen, Jianhua You, Li'e Lin, et al.
Annals of Hematology|September 6, 2020
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center studyJing Li, Li Bao, Zhongjun Xia, et al.
JAMA Oncology|November 7, 2024
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical TrialChunrui Li, Keshu Zhou, Yongxian Hu, et al.
International Journal of Cancer|February 24, 2018
Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) studyZimin Sun, Huilan Liu, Chenhui Luo, et al.
Cancer|December 21, 2022
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in ChinaYan Gao, Yizhen Liu, Yafei Wang, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 22, 2023
Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement: analysis of a series of 1090 cases in ChinaZhijuan Lin, Jie Zha, Shuhua Yi, et al.
Frontiers in Medicine|February 19, 2021
YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical TrialWeiping Liu, Yufu Li, Quanshun Wang, et al.
Journal of Hematology & Oncology|August 24, 2021
Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in ChinaJie Zha, Liyuan Fan, Shuhua Yi, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
American Journal of Hematology|April 26, 2026
Outcomes With First-Line PD1 Inhibitors in Extranodal NK/T-Cell Lymphoma: A Comparative Analysis From a 755-Patient Multicenter CohortHailing Liu, Mei Sun, Chunling Wang, et al.
Haematologica|July 9, 2026
Dual resistance to asparaginase and PD-1 blockade in extranodal natural killer/T-cell lymphoma: dismal outcomes from a multicenter cohortRan Li, Lixia Sheng, Jie Ma, et al.
Chinese Medical Journal|May 29, 2025
Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myelomaWenting Chen, Jianhua You, Li'e Lin, et al.
Annals of Hematology|September 6, 2020
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center studyJing Li, Li Bao, Zhongjun Xia, et al.
JAMA Oncology|November 7, 2024
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical TrialChunrui Li, Keshu Zhou, Yongxian Hu, et al.
International Journal of Cancer|February 24, 2018
Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) studyZimin Sun, Huilan Liu, Chenhui Luo, et al.
Cancer|December 21, 2022
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in ChinaYan Gao, Yizhen Liu, Yafei Wang, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 22, 2023
Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement: analysis of a series of 1090 cases in ChinaZhijuan Lin, Jie Zha, Shuhua Yi, et al.
Frontiers in Medicine|February 19, 2021
YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical TrialWeiping Liu, Yufu Li, Quanshun Wang, et al.
Journal of Hematology & Oncology|August 24, 2021
Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in ChinaJie Zha, Liyuan Fan, Shuhua Yi, et al.
Pageof 5